These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24338468)

  • 1. Intermittent versus every-day mesalazine therapy in preventing complications of diverticular disease: a long-term follow-up study.
    Tursi A; Di Mario F; Brandimarte G; Elisei W; Picchio M; Loperfido S; Dal Bo' N; Ferrara F; Marcello R; Heras Salvat H; Scarpignato C
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(23):3244-8. PubMed ID: 24338468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up.
    Comparato G; Fanigliulo L; Cavallaro LG; Aragona G; Cavestro GM; Iori V; Maino M; Mazzocchi G; Muzzetto P; Colla G; Sianesi M; Franzé A; Mario FD
    Dig Dis Sci; 2007 Nov; 52(11):2934-41. PubMed ID: 17410435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials.
    Picchio M; Elisei W; Tursi A
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):291-297. PubMed ID: 30240473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials.
    Picchio M; Elisei W; Brandimarte G; Di Mario F; Malfertheiner P; Scarpignato C; Tursi A
    J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S64-9. PubMed ID: 27622370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease.
    Gatta L; Di Mario F; Curlo M; Vaira D; Pilotto A; Lucarini P; Lera M; Enkleda K; Franzé A; Scarpignato C
    Intern Emerg Med; 2012 Apr; 7(2):133-7. PubMed ID: 21279478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon.
    Tursi A; Brandimarte G; Daffinà R
    Dig Liver Dis; 2002 Jul; 34(7):510-5. PubMed ID: 12236485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials.
    Khan RMA; Ali B; Hajibandeh S; Hajibandeh S
    Colorectal Dis; 2018 Jun; 20(6):469-478. PubMed ID: 29520987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.
    Iannone A; Ruospo M; Wong G; Barone M; Principi M; Di Leo A; Strippoli GFM
    Can J Gastroenterol Hepatol; 2018; 2018():5437135. PubMed ID: 30320044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study.
    Tursi A; Brandimarte G; Elisei W; Picchio M; Forti G; Pianese G; Rodino S; D'Amico T; Sacca N; Portincasa P; Capezzuto E; Lattanzio R; Spadaccini A; Fiorella S; Polimeni F; Polimeni N; Stoppino V; Stoppino G; Giorgetti GM; Aiello F; Danese S
    Aliment Pharmacol Ther; 2013 Oct; 38(7):741-51. PubMed ID: 23957734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence.
    Tursi A; Elisei W; Giorgetti GM; Inchingolo CD; Nenna R; Picchio M; Maiorano M; Penna A; Lecca PG; Brandimarte G
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):342-8. PubMed ID: 23426537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
    Brandimarte G; Tursi A
    Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis.
    Festa V; Spila Alegiani S; Chiesara F; Moretti A; Bianchi M; Dezi A; Traversa G; Koch M
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1397-1404. PubMed ID: 28387885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon.
    Tursi A; Brandimarte G; Giorgetti GM; Elisei W
    Hepatogastroenterology; 2008; 55(84):916-20. PubMed ID: 18705297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study.
    Tursi A; Brandimarte G; Giorgetti GM; Elisei W
    J Clin Gastroenterol; 2006 Apr; 40(4):312-6. PubMed ID: 16633103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of mesalazine in the treatment of symptomatic diverticular disease.
    Di Mario F; Aragona G; Leandro G; Comparato G; Fanigliulo L; Cavallaro LG; Cavestro GM; Iori V; Maino M; Moussa AM; Gnocchi A; Mazzocchi G; Franzé A
    Dig Dis Sci; 2005 Mar; 50(3):581-6. PubMed ID: 15810646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration.
    Parente F; Bargiggia S; Prada A; Bortoli A; Giacosa A; Germanà B; Ferrari A; Casella G; De Pretis G; Miori G;
    Int J Colorectal Dis; 2013 Oct; 28(10):1423-31. PubMed ID: 23754545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of mesalazine in diverticular disease.
    Di Mario F; Comparato G; Fanigliulo L; Aragona G; Cavallaro LG; Cavestro GM; Franzé A
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S155-9. PubMed ID: 16885700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease.
    Tursi A; Brandimarte G; Elisei W; Giorgetti GM; Inchingolo CD; Aiello F
    Dig Liver Dis; 2008 Sep; 40(9):737-42. PubMed ID: 18387861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study.
    Kruis W; Meier E; Schumacher M; Mickisch O; Greinwald R; Mueller R;
    Aliment Pharmacol Ther; 2013 Apr; 37(7):680-90. PubMed ID: 23414061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role of the Endoscopic Classification "DICA".
    Tursi A; Brandimarte G; Di Mario F; Elisei W; Scarpignato C; Picchio M
    J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S16-9. PubMed ID: 27622352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.